Italian lab to test cell capsules for diabetes

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Avaí Bio and Austrianova began work with Ospedale San Raffaele on protecting lab-grown insulin cells from the immune system.

Nobody in diabetes research is short of ambition. The dream of swapping out the insulin-making cells the body has lost has been around for a long time, and so has its biggest obstacle. Transplanted cells get attacked by the immune system. A new collaboration in Italy wants to see whether a tiny protective capsule can help.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3695

Avaí Bio

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Avaí Bio is an emerging biotechnology company specializing in genetically modified cell-based therapies designed to address metabolic and age-related disorders. The company develops encapsulated cellular therapeutics targeting type 1 and insulin-dependent type 2 diabetes, as well as age-related diseases through its α-Klotho protein overexpression program. By combining proprietary cell engineering with protective encapsulation technology, Avaí Bio aims to deliver immunosuppression-free treatment solutions that extend healthy lifespan and improve patient outcomes across multiple therapeutic domains.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE